News & Events

« Back to News & Events

Diplomat Specialty Pharmacy Provides Stelara™(ustekinumab) for Moderate To Severe Plaque Psoriasis

02 October 09

Swartz Creek, Mich., Sept 28, 2009—Diplomat Specialty Pharmacy announced today that their Psoriasis Navigator Program is providing Stelara™(ustekinumab) for adult patients with moderate to severe plaque psoriasis. Diplomat Specialty Pharmacy is a leading Immunology Biologics specialty pharmacy.

Through its Psoriasis Navigator Program Diplomat provides the following support for patients requiring Stelara™:

  • Initiate and manage entire insurance prior authorization assistance
  • Assist patients with all insurance issues including Appeals and Denials
  • Seek financial assistance from any available Patient Assistance Fund
  • Coordinate Medicare donut hole assistance
  • Coordinate Stelara™ Support Co-pay Assistance Cards for all eligible patients
  • Coordinate delivery of Stelara™ with each office visit

Healthcare providers and patients interested in enrolling in the Psoriasis Navigator Program should please call Diplomat’s Psoriasis Patient Care Center at: 1.866.311.9966 and ask for Stelara™ assistance.

About Diplomat Specialty Pharmacy

Diplomat Specialty Pharmacy is the nation’s largest privately held Specialty Pharmacy and focuses on complete medication management programs for patients with serious and chronic conditions. Key programs include: Oncology, HIV/AIDS, Hepatitis C, Multiple Sclerosis, Rheumatoid Arthritis, Crohn’s, Hemophilia, Growth Hormone and Psoriasis. Other specialty areas include Transplant, Fertility, Dialysis Medication Management, Bio-Identical Hormone Replacement Therapy and Specialty Compounding. The company also specializes in Disease Management programs for Chronic Kidney Disease patients, as well as Home and Out-Patient Infusion. With locations in Flint, Swartz Creek and Grand Rapids, MI; Cleveland, OH; Chicago, IL; and Ft. Lauderdale, Florida; Diplomat services the specialty pharmacy needs of patients and physicians nationwide.

More About Stelara™

Stelara™ Is Approved by FDA for Moderate to Severe Plaque Psoriasis

Stelara™ (ustekinumab), manufactured by Centocor Ortho Biotech, was approved by the FDA for the treatment of adult patients with moderate to severe plaque psoriasis. Stelara™ is an interleukin-12 andinterleukin-23 antagonist and the first drug in its class on the market.

In clinical trials, at least 65% to 75% of patients achieved a reduction in the Psoriasis Area and SeverityIndex (PASI) – 75 score compared to only 4% of patients on placebo.

Stelara™ is administered once every 12 weeks by subcutaneous injection and must be administered bya healthcare professional. As with tumor necrosis factor (TNF) inhibitors, Stelara™ may increase the riskof infections, including tuberculosis, and may increase the risk of malignancies. The FDA is requiring aRisk Evaluation and Mitigation Strategy (REMS) for Stelara™ that includes communication with healthcare providers and a medication guide for patients.

For more information, visit www.centocor.com